INTENSITY THERAPEUTICS, INC.
INTSNasdaq
$4.75
↓ -3.1%Jul 17 close · end-of-day
Price
1Y↓ -41.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$12.0M
Enterprise Value
$1.8M
P/E
—
P/S
—
P/B
1.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$10.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-107.2%
ROIC
—
Debt / Equity
—
Net Cash
$10.2M
Return 1Y
-43.0%
Company profile
Intensity Therapeutics, Inc. is a clinical stage biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRx℠ discovery platform. Our principal executive offices are located at 61 Wilton Road, 3rd Floor, Westport, CT.
- CEO
- Lewis H. Bender
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 2
- Headquarters
- Connecticut
- Website
- intensitytherapeutics.com
Management & directors
- Talamo JosephChief Financial Officer
- Wesolowski John MPrincipal Accounting Officer
- Bender Lewis HPresident and CEO
Roles derived from SEC Form 4 filings.
Earnings
INTS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.96↓ -82.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$7.5M | -$8.3M | -$16.6M | -$12.0M |
| Net income | -$7.6M | -$10.5M | -$16.3M | -$11.6M |
| Diluted EPS | -$2.22 | -$1.38 | -$29.24 | -$8.56 |
| Operating cash flow | -$5.5M | -$7.2M | -$15.2M | -$9.2M |
| Free cash flow | — | — | — | — |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.1M | -$3.6M | -$3.2M | -$3.4M | -$2.7M | -$2.7M | -$3.1M | -$2.5M |
| Net income | -$5.0M | -$3.5M | -$3.2M | -$3.3M | -$2.5M | -$2.7M | -$3.1M | -$2.4M |
| Diluted EPS | -$0.36 | -$0.25 | -$28.29 | -$5.51 | -$0.13 | -$0.06 | -$2.86 | -$0.96 |
| Operating cash flow | -$4.2M | -$4.0M | -$2.7M | -$2.0M | -$2.5M | -$2.4M | -$2.4M | -$1.8M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 15, 2026
- 5d agoSoft Tissue Sarcoma Market Set for Significant Growth at a CAGR of 7.9% During the Forecast Period (2026-2036), Driven by Novel Therapies and Expanding Treatment Landscape | DelveInsightfinance.yahoo.com
- 5d agoIntensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)finance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Wesolowski John M· Principal Accounting Officer | Award | 3,688 | $3.49 | $12,852.68 | filing |
| 2026-06-30 | Talamo Joseph· Chief Financial Officer | Award | 1,093 | $3.49 | $3,809.11 | filing |
| 2026-03-26 | BENDER LEWIS H· President and CEO | Award | 37,749 | $6.11 | $230,646.39 | filing |
| 2025-12-31 | Talamo Joseph· Chief Financial Officer | Award | 14,482 | $0.26 | $3,794.28 | filing |
| 2025-12-31 | Wesolowski John M· Principal Accounting Officer | Award | 8,918 | $0.26 | $2,336.52 | filing |
| 2025-06-30 | Wesolowski John M· Principal Accounting Officer | Award | 69,745 | $0.26 | $18,203.45 | filing |
| 2025-06-30 | Talamo Joseph· Chief Financial Officer | Award | 14,179 | $0.26 | $3,700.72 | filing |
Latest 7 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.